Patent · US Active

CRF receptor antagonists and methods relating thereto

US7737154B2 · kind B2 · utility

0Cited by

6References

19Claims

0Family size

Assignee

SMITHKLINE BEECHAM (CORK) LIMITED · IE

Inventors

Zhiyong Luo · New City, US
Deborah Helen Slee · Encinitas, US
John Williams · San Diego, US

Key dates

Filing date	Dec 20, 2004
Grant date	Jun 15, 2010
Priority date	—
Expiry date	Oct 19, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.